Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4

Neoplasia

Volumn 13, Issue 12, 2011, Pages 1152-1161

  Ray, Paramita ^a   Lewin, Sarah A ^a   Mihalko, Laura Anne ^a   Schmidt, Bradley T ^a   Luker, Kathryn E ^a   Luker, Gary D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; FEMALE; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84855463581     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111076     Document Type: Article

References (35)

1. Bast RJ, Hennessy B, and Mills G (2009). The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9, 415-428.
2. Rattan R, Graham R, Maguire J, Giri S, and Shridhar V (2011). Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13, 483-491.
3. Zillhardt M, Christensen J, and Lengyel E (2010). An orally available smallmolecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 12, 1-10.
4. Kim S, Kim J, Kim S, Brantley E, Yun S, He J, Maya M, Zhang F, Wu Q, Lehembre F, et al. (2011). Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia 13, 167-179.
5. Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y, Liu J, Zhou K, Yao M, Gu J, et al. (2011). Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 13, 461-471.
6. Barbieri F, Bajetto A, and Florio T (2010). Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol 2010, 426956.
7. Jiang Y, Wu X, Shi B, Wu W, and Yin G (2006). Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol 103, 226-233.
8. Scotton C, Wilson J, Milliken D, Stamp G, and Balkwill F (2001). Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 61, 3.
9. Foussat A, Balabanian K, Amara A, Bochet-Delbos L, Durand-Gasselin I, Baleux F, Couderc J, Galanaud P, and Emilie D (2001). Production of stromal cell-derived factor 1 by mesothelial cells and effects of this chemokine on peritoneal B lymphocytes. Eur J Immunol 31, 350-359.
10. Scotton C, Wilson J, Scott K, Stamp G, Wilbanks G, Fricker S, Bridger G, and Balkwill F (2002). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62, 5930-5938.
11. Yuecheng Y and Xiaoyan X (2007). Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. Eur J Cancer Prev 16, 430-435.
12. Miyanishi N, Suzuki Y, Simizu S, Kuwabara Y, Banno K, and Umezawa K (2010). Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. Biochem Biophys Res Commun 403, 154-159.
13. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zhou L, Machelon V, et al. (2005). CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 65, 465-472.
14. Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey V, Richardson A, and Weinberg R (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
15. Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling M, and Menger M (2007). Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 9, 862-870.
16. Luker K, Gupta M, and Luker G (2008). Imaging CXCR4 signaling with firefly luciferase complementation. Anal Chem 80, 5565-5573.
17. Luker K, Gupta M, Steele J, Foerster B, and Luker G (2009). Imaging liganddependent activation of CXCR7. Neoplasia 11, 1022-1035.
18. Luker K, Mihalko L, Schmidt B, Lewin S, Ray P, Shcherbo D, Chudakov D, Luker G (2011). In vivo imaging of ligand receptor binding with Gaussia luciferase complementation. Nat Med, E-pub ahead of print December 4.
19. Shcherbo D, Shemiakina I, Ryabova A, Luker K, Schmidt B, Souslova E, Gorodnicheva T, Strukova L, Shidlovskiy K, Britanova O, et al. (2010). Near infrared fluorescent proteins. Nat Methods 7, 827-829.
20. Luker K, Steele J, Mihalko L, and Luker G (2010). Constitutive and chemokinedependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 29, 4599-4610.
21. Luker K, Gupta M, and Luker G (2009). Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7. Biotechniques 47, 625-632.
22. Luker K, Gupta M, and Luker G (2009). Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J 23, 823-834.
23. Tannous B, Kim D, Fernandez J, Weissleder R, and Breakefield X (2005). Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11, 435-443.
24. Smith M, Luker K, Garbow J, Prior J, Jackson E, Piwnica-Worms D, and Luker G (2004). CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64, 8604-8612.
25. Barbolina M, Kim M, Liu Y, Shepard J, Belmadani A, Miller R, Shea L, and Stack M (2010). Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res 8, 653-664.
26. Remy I and Michnick S (2006). A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods 3, 977-979.
27. De Clercq E (2003). The bicyclam AMD3100 story. Nat Rev Drug Discov 2, 581-587.
28. Zabel B, Wang Y, Lewen S, Berahovich R, Penfold M, Zhang P, Powers J, Summers B, Miao Z, Zhao N, et al. (2009). Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol 183, 3204-3211.
29. Zhang W, Navenot J, Haribabu B, Tamamura H, Hiramatu K, Omagari A, Pei G, Manfredi J, Fujii N, Broach J, et al. (2002). A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem277, 24515-24521.
30. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, et al. (2006). Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 66, 2181-2187.
31. Kulbe H, Hagemann T, Szlosarek P, Balkwill F, and Wilson J (2005). The inflammatory cytokine tumor necrosis factor-α regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 65, 10355-10362.
32. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, and Kikkawa F (2008). Involvement of SDF-1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122, 91-99.
33. Armstrong D, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L, Walker J, Burger R, and Group GO (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354, 34-43.
34. Hendrix C, Flexner C, MacFarland R, Giandomenico C, Fuchs E, Redpath E, Bridger G, and Henson G (2000). Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44, 1667-1673.
35. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, et al. (2011). CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 71, 5522-5534.